Want to see AU:ATX full AI Analyst Report?
Top Page
Amplia Therapeutics
(Sydney:ATX)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.14
▲(2.14% Upside)
Action:Reiterated
Date:08/30/26
The score is held down primarily by weak financial performance (revenue dropping to zero, persistent losses, and worsening cash burn), partially offset by a comparatively strong, low-leverage balance sheet. Technical indicators are broadly neutral and do not provide a strong positive catalyst, while valuation is constrained by a negative P/E tied to ongoing unprofitability.
Positive Factors
Strong Equity Cushion
Equity represents most of the asset base, providing a meaningful buffer against operating losses and supporting continued development. This cushion can improve financial resilience over the next several months, although it does not yet translate into profitable returns.
Negative Factors
Revenue Deterioration
The disappearance of revenue leaves the company dependent on funding and future clinical or commercial milestones rather than an established income stream. It also prevents fixed costs from being absorbed by sales, increasing execution risk over the next two to six months.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Equity Cushion
Equity represents most of the asset base, providing a meaningful buffer against operating losses and supporting continued development. This cushion can improve financial resilience over the next several months, although it does not yet translate into profitable returns.
Read all positive factors
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$74.43M
Dividend YieldN/A
Average Volume (3M)1.29M
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth21.23%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume868,971
30 Day Avg. Volume1,292,011
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside200.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Amplia Therapeutics Business Overview & Revenue Model
Company Description
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor o...
Amplia Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 3.78M | 4.45M | 1.19M | 1.98M |
| Gross Profit | -92.14K | 3.57M | 4.01M | 1.12M | 1.98M |
| EBITDA | -13.09M | -6.78M | -4.48M | -7.26M | -3.64M |
| Net Income | -7.71M | -6.57M | -4.50M | -6.24M | -3.64M |
Balance Sheet | |||||
| Total Assets | 41.44M | 22.94M | 14.85M | 18.68M | 24.48M |
| Cash, Cash Equivalents and Short-Term Investments | 27.85M | 10.86M | 3.39M | 9.26M | 14.61M |
| Total Debt | 341.11K | 13.89K | 1.59M | 2.27M | 2.10M |
| Total Liabilities | 1.97M | 1.91M | 3.43M | 2.85M | 2.64M |
| Stockholders Equity | 39.47M | 21.02M | 11.42M | 15.84M | 21.85M |
Cash Flow | |||||
| Free Cash Flow | -8.77M | -6.89M | -5.13M | -5.31M | -4.42M |
| Operating Cash Flow | -8.73M | -6.89M | -5.13M | -5.29M | -4.40M |
| Investing Cash Flow | -96.22K | -2.07K | -2.23K | -58.42K | -26.64K |
| Financing Cash Flow | 25.94M | 14.32M | -772.98K | -84.22K | 17.19M |
Amplia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.59B | 123.31 | 6.03% | ― | -68.00% | -86.31% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$127.44M | -1.51 | -1189.87% | ― | 53.78% | -206.24% | |
47 Neutral | AU$74.43M | -8.08 | -18.71% | ― | ― | 21.23% | |
45 Neutral | AU$66.98M | -17.83 | -68.12% | ― | ― | 29.55% | |
41 Neutral | AU$114.51M | -4.62 | -48.25% | ― | ― | -16.21% |
* Healthcare Sector Average
AU:ATX
Amplia Therapeutics
0.14
-0.04
-20.59%
AU:ENP
Tryptamine Therapeutics
0.04
<0.01
17.65%
AU:NEU
Neuren Pharmaceuticals Limited
19.74
0.13
0.66%
AU:PAR
Paradigm Biopharmaceuticals
0.23
-0.05
-16.67%
AU:ATH
Alterity Therapeutics
0.51
-0.15
-22.31%
AU:ZLD
Zelira Therapeutics
0.50
0.09
21.95%
Amplia Therapeutics Corporate Events
Amplia Wins Strong Shareholder Backing for AGM Resolutions and Capital Flexibility
Aug 28, 2026
Amplia Therapeutics said all resolutions at its 28 August annual general meeting were passed, including director elections, an additional 10% placement capacity, an increase in the non‑executive director fee pool and the issuance of zeroR...
Amplia Therapeutics Highlights Strong Pancreatic Cancer Data in AGM CEO Presentation
Aug 28, 2026
Amplia Therapeutics has released the CEO and Managing Director’s presentation for its Annual General Meeting for the year ended 31 March 2026. The presentation highlights the company’s focus on advancing narmafotinib (AMP945), a best-i...
Amplia Showcases Lead FAK Inhibitor as Pancreatic Cancer Data Strengthen Oncology Push
Aug 6, 2026
Amplia Therapeutics has released a presentation for the Bioshares Biotech Summit in Queenstown, where Managing Director Dr Chris Burns will outline the company’s strategy of targeting pancreatic cancer and other fibrotic indications with its...
Amplia bolsters narmafotinib case with comprehensive pancreatic cancer data
Jul 30, 2026
Amplia Therapeutics has highlighted new preclinical research on its lead FAK inhibitor narmafotinib in pancreatic cancer, now available on the bioRxiv server. The studies, led by Professor Paul Timpson at the Garvan Institute, explore how narmafot...
Amplia advances FAK inhibitor program with new trials, patent gains and board refresh
Jul 28, 2026
Amplia reported mature data from its ACCENT trial in metastatic pancreatic cancer showing that its FAK inhibitor narmafotinib, added to standard chemotherapy, delivered favourable safety and improved efficacy across key measures, including higher ...
Amplia Therapeutics Issues New Employee Incentive Options
Jul 15, 2026
Amplia Therapeutics has notified the ASX of the issue of 987,592 unquoted options under its employee incentive scheme. The options, exercisable at $0.19 and expiring on July 15, 2028, are not intended to be quoted on the exchange.The new options g...
Amplia Therapeutics Issues New Employee Incentive Options
Jul 15, 2026
Amplia Therapeutics has notified the market of the issue of 1,272,099 unquoted Zero Exercise Price Options under its employee incentive scheme. The options, which are not intended to be quoted on the ASX, were issued on July 15, 2026, and reflect ...
Amplia Therapeutics appoints Brett Carter as director amid progress in pancreatic cancer trials
Jul 6, 2026
Amplia Therapeutics Limited has filed an Initial Director’s Interest Notice announcing the appointment of Brett Anthony Carter as a director of the company, noting that he currently holds no relevant interests in Amplia’s securities. T...
Amplia strengthens board with industry deal-maker Brett Carter
Jul 5, 2026
Amplia Therapeutics has appointed biopharmaceutical executive Brett Carter as a non-executive director, strengthening its board as lead drug narmafotinib moves into later-stage development. Carter brings more than 25 years of global oncology, corp...
Amplia Therapeutics Sets August AGM Amid Progress in FAK Cancer Trials
Jun 30, 2026
Amplia Therapeutics has scheduled its Annual General Meeting for Friday 28 August 2026, covering the financial year ended 31 March 2026, with venue and detailed arrangements to be confirmed. The company has also opened nominations for the election...
Amplia Therapeutics reshapes board leadership as clinical momentum builds
Jun 29, 2026
Amplia Therapeutics has announced a planned change in board leadership as part of its renewal and succession strategy, with long-serving chairman Dr Warwick Tong stepping down from the chair role while remaining on the board as a non-executive dir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.